Precision BioSciences Q3 EPS $(0.07) Beats $(0.17) Estimate, Sales $13.12M Beat $8.60M Estimate
Portfolio Pulse from Benzinga Newsdesk
Precision BioSciences (NASDAQ:DTIL) reported Q3 losses of $(0.07) per share, beating the analyst consensus estimate of $(0.17) by 58.82%. The company also reported quarterly sales of $13.12 million, surpassing the analyst consensus estimate of $8.60 million by 52.56%. Both figures represent significant increases over the same period last year.
November 07, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precision BioSciences reported better than expected Q3 results, with both EPS and sales beating estimates. This could potentially lead to a positive market reaction.
Precision BioSciences reported Q3 results that exceeded analyst expectations, with both EPS and sales beating estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100